UBS Group
HCWB icon

UBS Group’s HCW Biologics HCWB Stock Holding History

UBS Group’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11 Buy
6
+5
+500% +$15 ﹤0.01% 11057
2026
Q2 		$5 Sell
1
-1,536
-100% -$8.71K ﹤0.01% 10350
2026
Q1 		$3.32K Buy
1,537
+1,247
+430% +$6.45K ﹤0.01% 9109
2025
Q4 		$1.69K Buy
+290
New +$4.93K ﹤0.01% 9495
2025
Q3 		– Sell
-1,586
Closed -$37.7K – 10549
2025
Q2 		$37.7K Buy
+1,586
New +$69.2K ﹤0.01% 8007
2024
Q4 		– Sell
-20
Closed -$2.6K – 10121
2024
Q3 		$2.6K Buy
20
+2
+11% +$273 ﹤0.01% 8402
2024
Q2 		$2.77K Buy
18
+15
+500% +$4.43K ﹤0.01% 8303
2024
Q1 		$1.06K Hold
3
– – ﹤0.01% 8243
2023
Q4 		$778 Buy
3
+2
+200% +$682 ﹤0.01% 8516
2023
Q3 		$403 Buy
+1
New +$495 ﹤0.01% 8520
2023
Q2 		– Hold
0
– -$22 – 9193
2023
Q1 		– Sell
-2
Closed -$866 – 9412
2022
Q4 		$732 Buy
+2
New +$1.03K ﹤0.01% 10087
2022
Q3 		– Sell
-9
Closed -$5K – 10572
2022
Q2 		$5K Buy
9
+2
+29% +$1.12K ﹤0.01% 8878
2022
Q1 		$5K Buy
+7
New +$3.73K ﹤0.01% 9126
2021
Q4 		– Sell
-156
Closed -$119K – 10434
2021
Q3 		$119K Buy
+156
New +$164K ﹤0.01% 5704

Other funds holding HCWB

Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Golden State Wealth Management
Golden State Wealth Management Santa Ana, California $1.1B AUM 19.2% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

UBS Group's HCWB Position: Q3 2026 in Review

UBS Group increased its HCW Biologics (HCWB) stake by 500% in Q3 2026, buying an estimated $15 and bringing the position to 6 shares worth $11. The position accounts for ﹤0.01% of the portfolio, ranked #11057.

UBS Group first reported a position in HCWB in Q3 2021 and has held it in 14 quarters since. The position peaked at $119K in Q3 2021. 8 funds tracked by Wall St. Rank hold HCWB as of Q3 2026.

  • UBS Group held 6 shares of HCW Biologics worth $11 as of Q3 2026.
  • UBS Group bought 5 HCW Biologics shares in Q3 2026, an estimated $15.
  • HCW Biologics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #11057 holding.
  • UBS Group first reported a position in HCW Biologics in Q3 2021 and has held it in 14 quarters since.
  • UBS Group's HCW Biologics position peaked at $119K in Q3 2021.
  • 8 funds tracked by Wall St. Rank held HCW Biologics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.